WHO Approves Phase 2/3 Trials for Two Ebola Bundibugyo Vaccine Candidates in DRC

WHO has approved Phase 2/3 trials for two vaccine candidates targeting the Ebola Bundibugyo virus species, which is causing an outbreak in the Democratic Republic of Congo. Trials could begin within three to four weeks pending DRC regulatory approval. This marks a significant step in addressing a specific Ebola species with limited prior vaccine coverage.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works